Log In Get Started
Insider Trading March 17, 2026

CBIZ Director Makes Small Open-Market Purchase as Company Trades Near 52-Week Low

Director Rodney A. Young bought 1,000 shares on March 13, 2026; CBIZ reports revenue gains but posted an adjusted EPS loss in Q4 2025

By Avery Klein CBZ
CBIZ Director Makes Small Open-Market Purchase as Company Trades Near 52-Week Low
CBZ

Rodney A. Young, a director of CBIZ, Inc. (NYSE: CBZ), acquired 1,000 shares of the company's common stock on March 13, 2026, for $26,055. The purchase leaves Young with 9,310 directly held shares. The transaction occurs while CBIZ shares trade close to a 52-week low and after the company reported fourth-quarter revenue growth tied to the Marcum acquisition alongside an adjusted diluted EPS loss that modestly missed expectations.

Key Points

  • Director Rodney A. Young purchased 1,000 CBIZ shares on March 13, 2026 at $26.055, totaling $26,055 and increasing his direct holdings to 9,310 shares.
  • CBIZ shares are trading near a 52-week low of $25.45 and are down 49% year-to-date; InvestingPro flags the stock as trading below its Fair Value and notes nine additional insights on the company.
  • CBIZ reported Q4 2025 revenue of $543 million, an 18% year-over-year increase attributed mainly to the Marcum acquisition, while adjusted diluted EPS was a $0.70 loss, slightly below the $0.6408 forecast.

CBIZ, Inc. (NYSE: CBZ) recorded an insider purchase on March 13, 2026, when director Rodney A. Young bought 1,000 shares of common stock, according to a Form 4 filing submitted to the Securities and Exchange Commission. The shares were acquired at $26.055 apiece, bringing the total cash outlay for the trade to $26,055. Following this open-market purchase, Young's direct ownership of CBIZ common shares stands at 9,310.

The timing of the purchase coincides with notable weakness in the company’s share price. CBIZ is trading near its 52-week low of $25.45 and has posted a year-to-date decline of 49%. Market-data analysis referenced in the filing notes that InvestingPro considers the stock undervalued at current levels and that the platform highlights nine additional insights regarding the firm's financial profile and market position.

Earlier corporate disclosures show CBIZ delivered fourth-quarter and full-year 2025 results that combined revenue growth with an adjusted earnings shortfall. For the fourth quarter, the company reported revenue of $543 million, an 18% increase from the same quarter a year earlier. Management attributed the revenue increase primarily to the acquisition of Marcum. Despite the top-line expansion, CBIZ reported an adjusted diluted loss per share of $0.70 for the quarter, a figure that slightly exceeded the consensus loss forecast of $0.6408.

These filings and results frame the context for the director's purchase: a modest-sized, disclosed insider buy while the stock is under pressure and after a quarter of revenue growth that coincided with an acquisition but also included an earnings miss. The Form 4 filing is the formal disclosure vehicle for the trade and establishes the transaction details available to the market.

What this means

  • Director Rodney A. Young increased his direct stake by 1,000 shares at $26.055 per share on March 13, 2026.
  • The purchase occurred while CBIZ shares were trading close to their 52-week low and sharply lower year-to-date.
  • CBIZ reported Q4 2025 revenue growth of 18% to $543 million, driven primarily by the Marcum acquisition, while adjusted diluted EPS for the quarter was a $0.70 loss, modestly worse than the $0.6408 forecast.

Risks

  • Adjusted diluted EPS for Q4 2025 was a $0.70 loss, modestly exceeding the forecasted loss of $0.6408 - a shortfall that signals earnings pressure in the near term.
  • The stock is trading near its 52-week low ($25.45) and has declined 49% year-to-date, reflecting market valuation risk and price volatility for investors.
  • Available public commentary is limited to the Form 4 disclosure, InvestingPro valuation notes, and the Q4/2025 results; additional detail beyond these items is not provided in the filings referenced.

More from Insider Trading

Amplify Energy Director Sells Nearly 1 Million Shares as Company Executes Financial Moves Mar 17, 2026 Neurogene Chief Scientific Officer Disposes of $141K in Shares; Company Advances NGN-401 Program Mar 17, 2026 Grocery Outlet Officer Sells $22,452 in Stock as Company Grapples with Softening Metrics Mar 17, 2026 Grocery Outlet Director Increases Stake with $702,617 in Purchases Mar 17, 2026 Harvard Bioscience CEO Buys $25,050 of Stock as Company Posts Mixed Q4 Results and Sets 2026 Targets Mar 17, 2026